INTRODUCTION
variant protein has an increased molecular mass (95 kDa versus 65 kDa), as judged by SDS/PAGE, which is caused by its Factor IX is the zymogen of a serine protease that plays a key covalent binding to a protein of approximately 30 kDa through role in the coagulation cascade [1, 2] . Factor IXa activates factor a disulphide bond [9] . Factor IX Zutphen can not be activated X by limited proteolysis in the presence offactor VIlla, negatively by factor XIa, factor Xa/phospholipid or RW-X (factor X charged phospholipids and Ca2+ [3, 4] . In the mature factor IX, activating enzyme from Russell viper venom), which can explain the first 12 glutamic acid residues have been post-translational the severe haemophilia B phenotype of the patient [8] . modified to y-carboxyglutamic acid (Gla) residues [5] . Gla
In this study we further elucidated the relationship between the residues are involved in the binding of calcium to the N-terminal structural and functional defects of factor IX Zutphen. For this domain (Gla-domain) of factor IX.
we identified the 30 kDa protein and the molecular defect at the Binding of calcium induces a conformational change in factor genetic level. We used conformation-specific antibodies to de-IX, which can be monitored with conformation-specific antitermine how far the mutation and the presence of the complex bodies [6, 7] . On the basis of the metal ion selectivity of the prevented the formation of the different metal ion-induced binding to these conformation-dependent antibodies, a threeconformations. Furthermore, by studying the metal ion destate model has been proposed for this conformational change.
pendence of the binding to these antibodies we determined the The initial conformational transition (factor IX -+ factor IX') is effect of the mutation and the presence of the complex on the non-selective for metal ions, such as Ca2l, Mg2+, Mn2+ and Ba2l. relative stability of the metal-induced conformations. We were This conformation can be recognized by anti-factor IX: Mg (II) able to correlate these data with the observed functional defects antibodies. A further conformational transition (factor IX'-+ of factor IX Zutphen. factor IX*) is only supported by Ca2+ and Sr2+ ions, and is necessary for phospholipid binding and activation by factor XIa EXPERIMENTAL [7] . The factor IX* conformation can be recognized by antiMaterials factor IX: Ca(II) as well as anti-factor IX: Mg(II) antibodies.
Previously 
Identffication of the mutation
All of the coding regions and their flanking regions, the promoter region and the 3'-untranslated region of the factor IX gene of the patient with factor IX Zutphen were analysed, using PCR and direct sequencing of the amplified regions as described previously [10] .
Proteins
Normal factor IX and factor IX Zutphen were isolated from (patient) plasma, essentially according to previously published methods, consisting of barium citrate precipitation [11] , ammonium sulphate precipitation [12] and affinity chromatography on a non-Ca(II)-dependent monoclonal antibody (E12)-Sepharose 4B column. Bound factor IX was eluted from the column with 0.1 M glycine (pH 2.5). Both normal (65 kDa) and variant factor IX (95 kDa) were more than 95 % pure, as analysed by SDS/PAGE. Cys-carboxyamidomethylated normal factor IX (factor IX-AcN) was prepared by reducing normal factor IX with dithiothreitol (DTT) and carboxyamidomethylating the cysteine residues with iodoacetamide, following a standard procedure [13] . The 30 kDa polypeptide was isolated by separation from factor IX Zutphen, isolated from the plasma of a carrier of the mutation (containing both normal factor IX and factor IX Zutphen). After treatment with 20 mM DTT in 20 mM sodium citrate containing 0.9 % NaCl and 10 mM benzamidine for 60 min at 37°C, factor IX was precipitated by addition of 80 1l of 1 M BaCl2/ml. After centrifugation, the supernatant, which contained only one (30 kDa) band on reduced SDS/ PAGE, was dialysed extensively against 10% acetic acid and lyophilized.
Anti-factor IX: Ca(II), anti-factor IX: Mg(II) and non-Ca(II)-dependent antibodies against human factor IX were fraction'ated by affinity purification from rabbit anti-factor IX serum as described previously [6, 7] . The synthetic peptide factor IX(34-50) was synthesized on a solid-phase peptide synthesizer, using standard [(9-fluorenylmethyl)oxy]carbonyl (FMOC) chemistry (Department of Immunohaematology, University Hospital, Leiden, The Netherlands). The peptide was conjugated to rabbit serum albumin by glutaraldehyde and used to immunize a New Zealand White rabbit following standard protocols [14] . Antifactor IX(34-50) antibodies were isolated from rabbit serum by affinity chromatography on Protein A-Sepharose 4B [14] . Molar concentrations of factor IX preparations were calculated either directly from the protein content, using a molecular mass of 57 kDa and an A280 of 13.3 [15] , or from the antigen concentration determined in an ELISA using non-Ca(II)-dependent antibodies and a calibrated standard.
Protein analysis
The N-terminal sequence of the 30 kDa polypeptide was determined at the gas-phase sequenator facility [17] . Protein bands were visualized by silver staining according to Morrissey [18] or transferred to PVDF using a semi-dry blotting system (Pharmacia, Uppsala, Sweden). Proteins were detected with specific antibodies, conjugated to HRP. HRP-activity was visualized, using a chemiluminescence kit (Boehringer, Mannheim, Germany).
Activation of factor IX
Factor IX was activated by factor XIa by adding 5 ,ul of factor XIa (10 and quantified by measuring the A450 after stopping the reaction with H2S04 [19] . The relative amount of factor IX-a,M complex in plasma was determined in a sandwich ELISA analogous to the factor IX ELISA, but using anti-a1M-HRP as the conjugate.
Binding to anti-factor IX: Ca(ll), anti-factor IX: Mg(ll) or phospholipids Metal ion-dependent antibodies or isolated human brain phospholipids [20] , were coated as for the factor IX ELISA. Figure 1, lanes 5) . N-terminal sequencing of the peptide allowed the identification of residues 8-18 of the polypeptide as DNIQVQENF(Y)I. This information was used for a database search, performed at the NCBI using the BLAST network service [22] . Only one single perfect match was found with residues [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] of alM [23] , also called protein HC [24] . The factor IX Zutphen-ocM complex results directly from the Cys1 -+ Arg mutation
Six carriers and four non-carriers from the family of the patient [8] were screened by immunoblotting with the anti-a,M antibody for the presence of an identical complex in their plasma. The complex could be detected in the barium citrate eluate of the plasma of each carrier, whereas it was absent in the eluates of non-carriers (results not shown). The co-segregation of the mutation with the presence of the complex in the barium citrate eluates shows that this complex results from the point mutation and not from another pathological origin. The presence of the complex was also demonstrated directly in plasma of the patient and one carrier of the defect (individual IV-4 in the original pedigree [8] ), using a specific sandwich ELISA (Figure 2 ). The isolated factor IX Zutphen was used as a control. This shows that the complex is not an artifact of the barium citrate precipitation technique. The low, but significant, amount of the complex that can be detected in normal plasma (Figure 2 ) is in agreement with the observation of a trace amount of a 95 kDa band that reacts with anti-factor IX antibodies as well as anti-alM antibodies in immunopurified preparations of normal factor IX (results not shown).
Mutations which introduce free cysteine residues in factor IX normally give rise to very low antigen levels [27] . Apparently, factor IX Zutphen is rescued from intra-or extracelluar degradation by the formation of a complex with a1M. The reason why factor IX Zutphen forms a heterodimer with a1M and not with albumin, like some of the anti-thrombin and fibrinogen variants that contain a free cysteine residue [28] [29] [30] [31] [32] , is not obvious.
However, a.,M shares a remarkable homology in posttranslational processing with the vitamin K-dependent clotting factors with respect to the presence of N-linked and 0-linked carbohydrates, proteolytic cleavage at a dibasic site [33] [34] [35] and y-carboxylation [36] . This suggests that a1M and factor IX are localized in the same intracellular compartments. It would therefore be interesting to know whether a factor IX-a1M complex does exist for the Cys23 -+ Arg and Cys23 -. Tyr factor IX variants [27] , in which the disulphide loop in the Gla-domain is affected also. Antibodies were coated to microtitre plates and incubated with normal factor IX (U) and factor IX Zutphen (a) in the presence of 20 mM Ca2 . Plotted is the amount of bound factor IX, determined after elution with EDTA, as a function of the added amount of factor IX. To be able to compare the number of antigen binding sites for normal factor IX and factor IX Zutphen, they were incubated on the same plate. The results of one such experiment are shown.
Gia-analysis Factor IX Zutphen and normal factor IX were subjected to Glaanalysis. For both proteins, the calculated number of Glaresidues per mol was 11. This shows that the reported defective calcium-induced conformation [6, 8] is not caused by an impaired y-carboxylation. Furthermore this shows that the presence of the disulphide bond in the Gla-domain is no prerequisite for a fully carboxylated protein, as claimed by some authors [37] .
Factor IX Zutphen shows decreased binding to conformationspecffic antibodies
To determine how the mutation in factor IX Zutphen affected the calcium-induced conformation, we studied its binding to anti-factor IX: Ca(II) and anti-factor IX: Mg(II) antibodies. The dissociation constant (Kd) for the binding of normal factor IX to immobilized anti-factor IX: Ca(II) (Figure 3a) and anti-factor IX: Mg(II) antibodies (Figure 3b ) was determined in three (Figure 3a) . Although no complete saturation of binding of factor IX Zutphen to the anti-factor IX: Mg(II) antibodies could be accomplished, the Kd could be estimated as 45 + 15 nM (mean of three independent experiments) (Figure 3b ). The number of antigen binding sites for factor IX Zutphen was only 60 + 5 % of those for normal factor IX, indicating that only a fraction of the anti-factor IX: Mg(II) antibodies is able to recognize the factor IX' conformation of factor IX Zutphen. These data suggest that factor IX Zutphen can partially form the factor IX' conformation, but can not form the factor IX* conformation. However, the interpretation is complicated by the presence of the a,M peptide, which might interfere with antibody binding.
Therefore, factor IX Zutphen was separated from a1M by SDS/-PAGE under reducing conditions (Figure 4 ). This procedure still allowed normal factor IX (lane 3) to be recognized by the anti-factor IX: Ca(II) (Figure 4a ) and anti-factor IX: Mg(II) (Figure 4b disulphide bond is required for the factor IX* conformation, but that no disulphide bonds are required for the formation of the factor IX' conformation.
In factor IX Zutphen, the disulphide bond in the Gla-domain is the only disulphide bond that cannot reform after reduction and transfer to the membrane. Consequently, the inability of factor IX Zutphen to bind to the anti-factor IX: Ca(II) antibodies results from the inability to form the factor IX* conformation as a result of the absence of the disulphide bond in the Gla domain between Cysl8 and Cys23. The reduced affinity and avidity of the anti-factor IX: Mg(II) antibodies for factor IX Zutphen can, however, at least in part be explained by steric hindrance from a1M ( Figure 4) . Therefore, the factor IX' conformation may still be formed in factor IX Zutphen.
The metal ion-induced conformation of factor IX Zutphen is destabilized To determine the contribution of the disulphide bond to the formation of the factor IX' conformation, the metal ion dependence of the conformational change, as recognized by the anti-factor IX: Mg(II) antibodies, was studied ( Figure 5 ). At (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) antibodies to factor IX Zutphen, as can be judged from the identical dose-response curves for normal factor IX and factor IX Zutphen ( Figure 6 ). Similar to what was reported for antibodies raised against a synthetic peptide corresponding to residues 28-46 of human factor IX [38] , anti-factor IX(34-50) antibodies bind to factor IX only in the absence of metal ions. In the presence of saturating concentrations of Ca2+ or Mg2+ the binding of the antibody to normal factor IX as well as to factor IX Zutphen is equally strongly decreased ( Figure 6 ). The metal ion-induced internalization of residues 34-50 in normal factor IX and factor IX Zutphen can therefore be compared unambiguously. Similar to what was observed for the induction of the factor IX' conformation ( Figure  5 ), lower concentrations of Ca2+ (EC50 = 1.4 mM) than Mg2+ (EC50 = 2.9 mM) were needed to inhibit the binding of antifactor IX(34-50) to normal factor IX. The binding of factor IX Zutphen to anti-factor IX(34-50) antibodies was inhibited only by much higher concentrations of Ca2+ (EC50 = 7.2 mM) or Mg2+ (EC50 = 8.8 mM).
In conclusion, the metal ion-induced confomation, as monitored with both the anti-factor IX: Mg(II) and anti-factor IX(34-50) antibodies, is less stable in factor IX Zutphen than in normal factor IX. This destabilization can be caused by the 
Functional defects of factor IX Zutphen
Factor IX Zutphen showed no detectable binding for immobilized phospholipids (apparent Kd > 1 ,uM), whereas normal factor IX had an apparent Kd of 0.15 + 0.02 gM (results not shown). This is in agreement with the requirement of the factor IX* conformation for this process [7] .
Fab-fragments of anti-factor IX: Ca(II) antibodies inhibit the activation of factor IX by factor XIa, but still allow the formation of factor IXo by cleavage at residue Arg'45 [7] . The cleavage at Argx4s by factor XIa is less metal ion specific and can be supported by Mg2`ions ( [39] ; results not shown). This would mean that a correct factor IX' conformation would allow the (slow) cleavage at Arg145. Therefore the pattern of the cleavage of factor IX Zutphen by factor XIa was studied under conditions that factor IX Zutphen forms the factor IX' conformation. To be able to detect even minimal cleavage, we used enzyme:substrate ratios (1:30, w/w) that converted normal factor IX into IXa almost completely within 10 min (Figure 7a) . Under ( Figure 7b ). The band corresponding to the heavy chain of factor IXa was already present in the starting material. Although factor IX Zutphen may not fully express the factor IX' conformation at 20 mM CaCl2, we still would expect to detect cleavage of the protein fraction that did express the factor IX' conformation. The absence of any detectable cleavage suggests that steric hindrance from axM prevents the cleavage at Arg 45. Interestingly, factor IX-AcN was slowly cleaved only at Argt45 by factor XIa in the presence of 20 mM Ca2+ (results not shown). This indicates that complete reduction of factor IX, including the disulphide bond in the Gla domain, still allows the cleavage at Arg145
The functional defects of factor IX Zutphen therefore result from the combined effects of the Cys8 -Arg mutation: the disruption of the disulphide bond in the Gla domain prevents the formation of the factor IX* conformation, and consequently prevents phospholipid binding and cleavage at Arg180 by factor XIa, whereas the formation of the complex with acM results in steric hindrance which prevents the cleavage at Arg145 by factor XIa.
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